Superworth

Bausch Health Companies BHC

Drug Manufacturers - General, Healthcare
$8.02
−2.20%
Market cap
$3B
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
0.3×
EV/EBIT
10.5×
Revenue, 12 months
$11.1B
+11% on a year ago
Net margin
−7.6%
Free cash flow yield
n/m
a yield above 40% (usually a one-off)

Bausch Health Companies trades at 0.3× sales. Its trailing earnings are negative, so it has no PE. Revenue was $11.1B over the last twelve months, up 11% on a year earlier with a −8% net margin.

Charts

Financials

Income statement for BHC, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$2.4B+10%$2.2B+11%$2.4B+11%$2.5B+12%$2.6B+6%$2.3B+5%$2.5B+5%$2.7B+7%$2.8B+9%$2.5B+12%$2.9B+13%$2.9B+10%
Cost of revenue$705M+8%$640M+10%$719M+11%$696M+12%$727M+3%$701M+10%$764M+6%$750M+8%$798M+10%$738M+5%$772M+1%$735M−2%
Gross profit$1.7B+11%$1.5B+11%$1.7B+11%$1.8B+12%$1.8B+8%$1.6B+3%$1.8B+5%$1.9B+6%$2B+9%$1.8B+15%$2.1B+18%$2.2B+14%
R&D$152M+7%$151M+6%$156M+0%$146M−5%$163M+7%$143M−5%$159M+2%$166M+14%$161M−1%$163M+14%$173M+9%$141M−15%
SG&A$766M+15%$794M+10%$832M+17%$850M+19%$820M+7%$867M+9%$894M+8%$795M−7%$882M+8%$861M−1%$907M+2%$834M+5%
$362M$281M+61%$389M−6%$318M+2171%$558M+54%$276M−2%$444M+14%$619M+95%$474M−15%−$950M$740M+67%$983M+59%
Interest expense$363M+18%$355M+16%$350M+10%$346M+2%$337M−7%$330M−7%$465M+33%$412M+19%$397M+18%$402M+22%$396M−15%$398M−3%
Pre-tax income−$7M−98%−$69M−49%$48M−39%−$21M−94%$209M−$47M−32%$140M+192%$218M$56M−73%−$1.4B+2781%$348M+149%$597M+174%
$40M−25%$8M−89%$49M−6%$71M+27%$111M+178%$39M+388%$12M−76%$37M−48%$159M+43%$77M+97%$88M+633%$151M+308%
Net income−$39M−91%−$64M−68%$10M−62%−$85M−78%$93M−$58M−9%$148M+1380%$179M−$112M−$1.4B+2353%$258M+74%$436M+144%
−$0.11−90%−$0.17−69%$0.03−57%−$0.23−78%$0.25−$0.16−6%$0.40+1233%$0.48−$0.30−$3.82+2288%$0.68+70%$1.15+140%
366.1M+1%366.8M+1%370.2M+1%368.4M+1%368.9M+1%369.6M+1%373.1M+1%375.5M+2%371.8M+1%372.8M+1%378.1M+1%380.7M+1%

Gross profit: 69 periods, Q2 FY09 to Q3 FY26: not printed by the filing, worked out from its own lines.

Net income: 8 periods, Q3 FY11 to Q2 FY13: not printed by the filing, worked out from its own lines.

EPS, diluted: 15 periods, Q4 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 7 periods, Q4 FY09 to Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days. 10 periods, Q4 FY10 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Bausch Health Companies' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
BHCBausch Health Companies$3Bn/m12.0×0.3×+11%−7.6%
NRIXNurix Therapeutics$2.8B11.1×11.0×4.0×n/m42.0%
OGNOrganon$3.6B18.2×6.0×0.6×−3%3.5%
LQDALiquidia$3.7B30.1×49.4×8.3×n/m30.7%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
ARQTArcutis Biotherapeutics$3.9B142×117×8.5×+76%6.1%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
INDVIndivior Pharmaceuticals$4.3B10.2×19.9×3.1×+16%32.8%
ANIPANI Pharmaceuticals$1.6B15.0×57.5×1.7×+31%11.1%
PAHCPhibro Animal Health$1.6B15.9×21.5×1.0×+17%6.6%
LGNDLigand Pharmaceuticals$6.1B32.7×37.6×21.1×+55%67.9%
Peer median$3.2B15.5×20.7×2.7×+21%17.2%

More on Bausch Health Companies

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .